{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122426","form_type":"8-K","ticker":null,"cik":"0001061027","company_name":"Viracta Therapeutics, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.536728+00:00","generated_at":"2026-05-30T04:17:46.182045+00:00","sec_items":["2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Viracta cuts 42% of staff, reduces board to 6; focuses on Nana-val PTCL program","bullets":["Workforce reduction of ~42% to conserve resources for Nana-val development; expects $0.7M in severance costs.","Four directors (Barlow, Chung, Murphy, Rubino) resigned Oct 31; board size reduced from 10 to 6 seats.","Company prioritizing Nana-val for R/R EBV-positive PTCL toward potential NDA submission.","Actions intended to reduce cash burn and streamline operations; remaining board includes Chairman Pomerantz."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122426","json":"https://secwatch.observer/filing/0000950170-24-122426.json","markdown":"https://secwatch.observer/filing/0000950170-24-122426.md","text":"https://secwatch.observer/filing/0000950170-24-122426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024122426/0000950170-24-122426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024122426/virx-20241031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:17:46.182045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2888f0be37","claim":"Jane F. Barlow resigned as Director at Viracta Therapeutics, Inc..","evidence_excerpt":"On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024122426/0000950170-24-122426-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4e8da833ce","claim":"Stephen Rubino resigned as Director at Viracta Therapeutics, Inc..","evidence_excerpt":"On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024122426/0000950170-24-122426-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"53848a4007","claim":"Sam Murphy resigned as Director at Viracta Therapeutics, Inc..","evidence_excerpt":"On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024122426/0000950170-24-122426-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a74b885d49","claim":"Jane Chung resigned as Director at Viracta Therapeutics, Inc..","evidence_excerpt":"On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024122426/0000950170-24-122426-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"fdd1118c8a071f4c98adced1155b7dd633491446","claim":"Viracta Therapeutics, Inc. announced a restructuring with charges of approximately $0.7 million in total expenses for severance and related benefits for employees impacted by the reduction in force affecting Workforce reduction affecting approximately 42% of the Company's workforce (approximately 42% of the Company's workforce).","evidence_excerpt":"On October 31, 2024, Viracta Therapeutics, Inc. (the “Company”), committed to and implemented a reduction in force that impacted approximately 42% of the Company’s workforce. The Company expects to recognize approximately $0.7 million in total expenses for severance and related benefits for employees impacted by the reduction in force, consisting primarily of severance payments and related benefits.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024122426/0000950170-24-122426-index.htm","confidence":0.95,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $0.7 million in total expenses for severance and related benefits for employees impacted by the reduction in force"},{"label":"Affected area","value":"Workforce reduction affecting approximately 42% of the Company's workforce"},{"label":"Headcount","value":"approximately 42% of the Company's workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}